Diabetic Kidney Disease in Type 2 Diabetes: a Review of Pathogenic Mechanisms, Patient-related Factors and Therapeutic Options

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2021 May 12

PMID 33976959

Citations 6

Authors

Louise Woodhams

Tin Fei Sim

Leanne Chalmers

Bu Yeap

Daniel Green

Markus Schlaich

Carl Schultz

Graham Hillis

Affiliations

Soon will be listed here.

Abstract

The global prevalence of diabetic kidney disease is rapidly accelerating due to an increasing number of people living with type 2 diabetes. It has become a significant global problem, increasing human and financial pressures on already overburdened healthcare systems. Interest in diabetic kidney disease has increased over the last decade and progress has been made in determining the pathogenic mechanisms and patient-related factors involved in the development and pathogenesis of this disease. A greater understanding of these factors will catalyse the development of novel treatments and influence current practice. This review summarises the latest evidence for the factors involved in the development and progression of diabetic kidney disease, which will inform better management strategies targeting such factors to improve therapeutic outcomes in patients living with diabetes.

Citing Articles

Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology.

Adamczak M, Kurnatowska I, Naumnik B, Stompor T, Tylicki L, Krajewska M Int J Mol Sci. 2024; 25(23.

PMID: 39684653 PMC: 11641270. DOI: 10.3390/ijms252312941.

Potentials of Natural Antioxidants in Reducing Inflammation and Oxidative Stress in Chronic Kidney Disease.

Lee O, Wong A, Ho C, Tse K, Chan A, Leung G Antioxidants (Basel). 2024; 13(6).

PMID: 38929190 PMC: 11201162. DOI: 10.3390/antiox13060751.

Pathomechanisms of Diabetic Kidney Disease.

Sinha S, Nicholas S J Clin Med. 2023; 12(23).

PMID: 38068400 PMC: 10707303. DOI: 10.3390/jcm12237349.

Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes.

Siddiqui K, George T, Joy S, Alfadda A Front Endocrinol (Lausanne). 2022; 13:1079725.

PMID: 36568108 PMC: 9780388. DOI: 10.3389/fendo.2022.1079725.

Ameliorative Effects of Camel Milk and Its Exosomes on Diabetic Nephropathy in Rats.

Shaban A, Raslan M, Qahl S, Elsayed K, Abdelhameed M, Oyouni A Membranes (Basel). 2022; 12(11).

PMID: 36363614 PMC: 9697163. DOI: 10.3390/membranes12111060.

References

Jeon S . Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016; 48(7):e245. PMC: 4973318. DOI: 10.1038/emm.2016.81. View

Nakagawa T, Johnson R, Andres-Hernando A, Roncal-Jimenez C, Sanchez-Lozada L, Tolan D . Fructose Production and Metabolism in the Kidney. J Am Soc Nephrol. 2020; 31(5):898-906. PMC: 7217403. DOI: 10.1681/ASN.2019101015. View

Elajami T, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M, Welty F . Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. J Am Heart Assoc. 2017; 6(7). PMC: 5586259. DOI: 10.1161/JAHA.116.004740. View

Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S . CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci. 2002; 947:350-5. DOI: 10.1111/j.1749-6632.2001.tb03961.x. View

Sadeghian M, Azadbakht L, Khalili N, Mortazavi M, Esmaillzadeh A . Oral Magnesium Supplementation Improved Lipid Profile but Increased Insulin Resistance in Patients with Diabetic Nephropathy: a Double-Blind Randomized Controlled Clinical Trial. Biol Trace Elem Res. 2019; 193(1):23-35. DOI: 10.1007/s12011-019-01687-6. View

Vlassara H, Li Y, Imani F, Wojciechowicz D, Yang Z, Liu F . Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med. 1995; 1(6):634-46. PMC: 2229987. View

Thomas M . The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab. 2017; 43 Suppl 1:2S20-2S27. DOI: 10.1016/S1262-3636(17)30069-1. View

Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B . Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002; 25(11):1919-27. DOI: 10.2337/diacare.25.11.1919. View

Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K . Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005; 45(4):710-6. DOI: 10.1161/01.HYP.0000154681.38944.9a. View

10.

Rosca M, Vazquez E, Kerner J, Parland W, Chandler M, Stanley W . Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res. 2008; 80(1):30-9. PMC: 2533423. DOI: 10.1093/cvr/cvn184. View

11.

Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J . Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103(2):137-49. DOI: 10.1016/j.diabres.2013.11.002. View

12.

Rowlands J, Heng J, Newsholme P, Carlessi R . Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front Endocrinol (Lausanne). 2018; 9:672. PMC: 6266510. DOI: 10.3389/fendo.2018.00672. View

13.

Yang S, Zheng Y, Hou X . Lipoxin A4 restores oxidative stress-induced vascular endothelial cell injury and thrombosis-related factor expression by its receptor-mediated activation of Nrf2-HO-1 axis. Cell Signal. 2019; 60:146-153. DOI: 10.1016/j.cellsig.2019.05.002. View

14.

Wang Y, Li H, Song S . β-Arrestin 1/2 Aggravates Podocyte Apoptosis of Diabetic Nephropathy via Wnt/β-Catenin Pathway. Med Sci Monit. 2018; 24:1724-1732. PMC: 5881455. DOI: 10.12659/msm.905642. View

15.

Miranda-Diaz A, Pazarin-Villasenor L, Yanowsky-Escatell F, Andrade-Sierra J . Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease. J Diabetes Res. 2016; 2016:7047238. PMC: 4971321. DOI: 10.1155/2016/7047238. View

16.

Egido J, Rojas-Rivera J, Mas S, Ruiz-Ortega M, Sanz A, Gonzalez Parra E . Atrasentan for the treatment of diabetic nephropathy. Expert Opin Investig Drugs. 2017; 26(6):741-750. DOI: 10.1080/13543784.2017.1325872. View

17.

Liu B, Chen Y, Cheng H, Wang Y, Rui H, Yang M . The Protective Effects of Curcumin on Obesity-Related Glomerulopathy Are Associated with Inhibition of Wnt/β-Catenin Signaling Activation in Podocytes. Evid Based Complement Alternat Med. 2015; 2015:827472. PMC: 4619947. DOI: 10.1155/2015/827472. View

18.

Alpert E, Gruzman A, Riahi Y, Blejter R, Aharoni P, Weisinger G . Delayed autoregulation of glucose transport in vascular endothelial cells. Diabetologia. 2005; 48(4):752-5. DOI: 10.1007/s00125-005-1681-y. View

19.

Skrunes R, Svarstad E, Reisaeter A, Vikse B . Familial clustering of ESRD in the Norwegian population. Clin J Am Soc Nephrol. 2014; 9(10):1692-700. PMC: 4186510. DOI: 10.2215/CJN.01680214. View

20.

Wharram B, Goyal M, Wiggins J, Sanden S, Hussain S, Filipiak W . Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005; 16(10):2941-52. DOI: 10.1681/ASN.2005010055. View